ClinicalTrials.gg
Not yet recruitingNCT07612839LIDO-TAPPUpdated Sep 4, 2026

Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia Repair

An interventional study of Lidocaine and 0.9 % sodium chloride in Postoperative Fatigue Syndrome and Inguinal Hernia Unilateral, sponsored by Hakan Emirkadı. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Hakan Emirkadı · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 332 studies in Fatigue with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Fatigue · Turkey.

Planned enrollment
51st of 252
80 · median 60
Started
2026
with 41 others
No phase
249 of 332
37 open now
Primary completion
2026-12
later than 44 of 55 live
Registered
295th of 332
by date

Among the 332 studies in Fatigue with a site in Turkey, this one is the 51st largest by planned enrollment of the 252 interventional ones that give a count, is one of 42 that started in 2026, is one of 249 with no phase, reaches primary completion later than 44 of the 55 other live ones, and was the 295th registered.

Fatigue

2,234 studies on the registry are indexed under Fatigue; 430 are open to participants now.

Browse Fatigue studies →

Open to participants now

50 of the 332 studies in Fatigue with a site in Turkey are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 242 Fatigue studies recruiting now, 113 (47%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 332 studies in Fatigue with a site in Turkey, or all of them as a file.
02

Study summary

This prospective randomized placebo-controlled trial aims to evaluate the effect of perioperative intravenous lidocaine on postoperative fatigue in patients undergoing elective laparoscopic TAPP inguinal hernia repair. Participants will be randomly assigned to receive either intravenous lidocaine or an equal-volume 0.9% sodium chloride placebo. The primary outcome is postoperative physical fatigue assessed using the Physical Fatigue subscale of the Multidimensional Fatigue Inventory-20 (MFI-20). Secondary outcomes include postoperative pain, cumulative tramadol consumption, postoperative nausea and vomiting, and the requirement for additional analgesia.

Read the detailed description

Postoperative fatigue may negatively affect recovery after surgery. Intravenous lidocaine has analgesic, anti-inflammatory, and opioid-sparing properties that may influence postoperative recovery.

This prospective randomized placebo-controlled trial will include adult patients undergoing elective laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair under general anesthesia. Eligible participants will be randomly allocated to receive either perioperative intravenous lidocaine or an equal-volume 0.9% sodium chloride placebo according to the same administration schedule. Participants, anesthesia care providers, and postoperative outcome assessors will be blinded to treatment allocation.

The primary outcome is postoperative physical fatigue assessed using the Physical Fatigue subscale of the Multidimensional Fatigue Inventory-20 (MFI-20), with a preoperative baseline assessment and postoperative assessments on days 1, 3, 5, and 7. Secondary outcomes include postoperative pain intensity, cumulative tramadol consumption during the first 24 postoperative hours, postoperative nausea and vomiting, and the requirement for additional analgesia during the first 24 postoperative hours.

03

Conditions studied

  • Postoperative Fatigue Syndrome
  • Inguinal Hernia Unilateral

Keywords

  • Intravenous Lidocaine
  • Postoperative Fatigue
  • Laparoscopic TAPP Repair
  • Postoperative Recovery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years
  • Scheduled for elective laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair
  • (ASA) physical status I or II
  • Able to understand and complete the Multidimensional Fatigue Inventory-20 (MFI-20)
  • Written provided

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to lidocaine or other amide-type local anesthetics
  • hepatic or renal dysfunction
  • Clinically significant cardiac rhythm or conduction disorder
  • Chronic opioid use
  • Regular use of antiarrhythmic medication
  • Pregnancy or breastfeeding
  • Planned use of an additional local anesthetic technique during the study intervention
  • Inability to complete the study assessments
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Lidocaine Group

    Participants in this group will receive intravenous lidocaine based on ideal body weight. A loading dose of 1.5 mg/kg will be administered intravenously over 10 minutes before surgery, followed by a continuous infusion of 1.5 mg/kg/hour until the end of surgery. The infusion will be discontinued if signs suggestive of local anesthetic systemic toxicity or clinically significant unexplained hemodynamic or cardiac conduction abnormalities occur.

    Drug: Lidocaine

  • Placebo comparator
    Control Group

    Participants in this group will receive an equal-volume 0.9% sodium chloride placebo administered according to the same timing and infusion protocol as the lidocaine group. Standard perioperative care will otherwise be identical between groups.

    Drug: 0.9 % sodium chloride

Interventions

  • Perioperative intravenous lidocaine infusion will be administered according to the study protocol in patients undergoing elective laparoscopic TAPP inguinal hernia repair.

  • Drug0.9 % sodium chloride

    0.9% sodium chloride will be administered intravenously as placebo in an equal volume and according to the same timing and infusion protocol as the lidocaine intervention.

06

What researchers measure

Primary outcomes

  1. MFI-20 Physical Fatigue Subscale Score

    Postoperative physical fatigue will be assessed using the Physical Fatigue subscale of the Multidimensional Fatigue Inventory-20 (MFI-20). The Physical Fatigue subscale consists of four items and ranges from 4 to 20 points, with higher scores indicating greater physical fatigue. A preoperative assessment will be obtained as the baseline value. Postoperative assessments will be performed on postoperative days 1, 3, 5, and 7.

    Time frame: Preoperative baseline and postoperative days 1, 3, 5, and 7

Secondary outcomes

  1. Postoperative Pain Intensity (11-point Numeric Rating Scale)

    Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.

    Time frame: 2, 4, 6, 12, and 24 hours after surgery and postoperative days 3, 5, and 7

  2. Postoperative Nausea and Vomiting Within 24 Hours

    Postoperative nausea and vomiting (PONV) will be assessed during the first 24 hours after surgery. The occurrence of nausea and vomiting will be recorded separately, and the occurrence of either nausea or vomiting will be considered PONV.

    Time frame: First 24 hours after surgery

  3. Cumulative Tramadol Consumption During the First 24 Postoperative Hours

    Total tramadol consumption delivered through patient-controlled analgesia (PCA) during the first 24 hours after surgery will be recorded in milligrams. Higher values indicate greater postoperative opioid requirement.

    Time frame: First 24 hours after surgery

  4. Requirement for Additional Analgesia During the First 24 Postoperative Hours

    The requirement for additional analgesia with intravenous paracetamol during the first 24 hours after surgery will be recorded. The number and proportion of participants requiring at least one dose of additional analgesia will be compared between groups.

    Time frame: First 24 hours after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared because the study involves sensitive clinical data and no public data-sharing plan has been established.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 937 non-industry interventional studies with no phase under Fatigue, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 3 months is below that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 29, 2026
StartEst.
Sep 2, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07612839
Lead sponsor
Hakan Emirkadı
Responsible party
Hakan Emirkadı (Anesthesiology and Reanimation Specialist, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey) — Sponsor-investigator
First posted
May 29, 2026
Start date
Sep 2, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Hakan Emirkadı, MD
Contact
hemirkadi@gmail.com
+905322609367

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion